2025 ASH  |  Gluetacs Discloses GT919 Phase I Clinic Results for Poster Rresentation At the Upcoming 67th American Society of Hematology (ASH) Annual Meeting

ON：2025-11-15 TAGS：GLUETACS THERAPEUTICS

On November 11, 2025, Gluetacs Therapeutics, an innovative clinical-stage biopharmaceutical technology enterprise specializing in protein degradation technology, announced that its proprietary IKZF3/1 molecular glue degrader, GT919, has been accepted for poster presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting.

GT919 is a novel, highly selective oral molecular glue degrader that targets IKZF3/1 via CRBN, a substrate receptor of the E3 ubiquitin ligase complex, leading to robust and sustained protein degradation. Both preclinical and clinical studies have shown that GT919 achieves effective IKZF3/1 degradation, resulting in robust immunomodulatory effects and antitumor activity in patients with relapsed or refractory multiple myeloma (R/R MM).

The ASH Annual Meeting is one of the world’s premier scientific conferences in hematology, bringing together global experts and leading researchers to showcase the latest breakthroughs and clinical advancements in blood disease research and treatment. The 67th ASH Annual Meeting will take place December 6–9, 2025, in Orlando, Florida, and will be held in a hybrid (in-person and virtual) format.

Gluetacs cordially invites you to interact with us at the 67th ASH Annual Meeting. You can contact us via E-mail (bd@gluetacs.com; james.mao@gluetacs.com) and meet our team at the conference.
For more information, please visit the 2025 ASH official website: https://www.hematology.org/meetings/annual-meeting